BNP Paribas Upgrades Genmab A/S (NASDAQ:GMAB) to “Hold”

BNP Paribas upgraded shares of Genmab A/S (NASDAQ:GMAB) from a strong sell rating to a hold rating in a report published on Tuesday morning,Zacks.com reports.

Several other brokerages also recently weighed in on GMAB. HC Wainwright reaffirmed a “buy” rating and set a $50.00 price target on shares of Genmab A/S in a research report on Thursday, January 23rd. Leerink Partners upgraded Genmab A/S from a “market perform” rating to an “outperform” rating and set a $27.00 price target for the company in a research report on Thursday. Sanford C. Bernstein upgraded Genmab A/S from a “strong sell” rating to a “hold” rating in a research report on Friday, December 20th. Finally, BMO Capital Markets reaffirmed an “outperform” rating and set a $48.00 target price (up from $46.00) on shares of Genmab A/S in a report on Friday, November 8th. Four investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $42.17.

Genmab A/S Stock Up 4.2 %

Genmab A/S stock opened at $19.69 on Tuesday. The stock has a 50-day moving average price of $20.68 and a 200 day moving average price of $23.21. The company has a market capitalization of $13.03 billion, a price-to-earnings ratio of 19.12, a price-to-earnings-growth ratio of 0.54 and a beta of 0.96. Genmab A/S has a 52 week low of $18.64 and a 52 week high of $31.88.

Genmab A/S (NASDAQ:GMAB) last announced its quarterly earnings data on Wednesday, February 12th. The company reported $0.57 EPS for the quarter, beating the consensus estimate of $0.28 by $0.29. Genmab A/S had a net margin of 23.49% and a return on equity of 14.64%. Research analysts anticipate that Genmab A/S will post 1.25 EPS for the current fiscal year.

Institutional Investors Weigh In On Genmab A/S

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Ritholtz Wealth Management purchased a new position in Genmab A/S during the third quarter valued at $314,000. Creative Planning raised its position in shares of Genmab A/S by 136.3% during the 3rd quarter. Creative Planning now owns 47,422 shares of the company’s stock worth $1,156,000 after purchasing an additional 27,353 shares during the last quarter. Bleakley Financial Group LLC lifted its stake in Genmab A/S by 7.7% in the 3rd quarter. Bleakley Financial Group LLC now owns 30,732 shares of the company’s stock valued at $749,000 after buying an additional 2,196 shares in the last quarter. Blue Trust Inc. boosted its holdings in Genmab A/S by 892.0% in the 3rd quarter. Blue Trust Inc. now owns 4,315 shares of the company’s stock worth $108,000 after buying an additional 3,880 shares during the last quarter. Finally, Raymond James & Associates increased its stake in Genmab A/S by 2.2% during the 3rd quarter. Raymond James & Associates now owns 169,747 shares of the company’s stock worth $4,138,000 after buying an additional 3,598 shares in the last quarter. Hedge funds and other institutional investors own 7.07% of the company’s stock.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.